“We want to consider Medicare coverage of new treatments very carefully in light of the evidence available. Our process will include opportunities to hear from many stakeholders, including patient advocacy groups, medical experts, states, issuers, industry professionals, and family members and caregivers of those living with this disease” CMS( Centers for Medicare and Medicaid Services) Administrator Chiquita Brooks-LaSure said in a statement